Repositioning Immunotherapy in VetArans With Lung Cancer

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

Trial Details

NCT ID
NCT06275360
Phase
PHASE2
Sponsor
VA Office of Research and Development
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Nivolumab
Locations (sample)
  • West Haven, Connecticut, United States|41.27065,-72.94705
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Patient must have a performance status of 0-1 (ECOG Performance Scale)
  • Patient must be a candidate for concurrent chemoradiation
  • Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment
  • PD-L1 tumor expression greater than or equal to 1%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →